Skip to content
Research Article Open access CC BY 4.0

Epidemiological Assessment and Challenges of the COVID-19 Pandemic in Nigeria

Stephen Olaide Aremu, Emmanuel Olumuyiwa Onifade, Babatunde Fatoke, Samuel Olusegun Itodo, Oluwatosin Oladipo, Olufisayo Bademosi, Temilade Taiwo Oleni, Tosin Adebola Ode, Ebenezer Oluwasanmi Abeleje, Adebowale Olasehinde Folorunso

Microbiology Research Journal International · pp. 11–29 · Published 13 Nov 2020

10.9734/mrji/2020/v30i930259

Abstract

The COVID-19 which belongs to the coronaviridae family has continued to spread in a geometric progression version. The disease that originated from Wuhan, Hubei, China has spread to all the continents of the World except Antarctica continent. As of the 5th of August, 2020 there are over 18 million reported cases of COVID-19 from 214 countries and territories of the world. More than 10 million people have recovered while approximately 696,147 people have died due to COVID-19. This review provides general information on the COVID-19 and gives deep insight into the course of the disease, interventions challenges and possible solutions in Nigeria “the giant of Africa”. Scientific databases including Science Direct, Pub Med, Elsevier, Scopus, and Nature were explored. Data has also been accessed from case reports, newspaper reports, internet data, World Health Organisation (WHO) reports, Centre of Disease Control (CDCs) and Nigerian Centre of Disease Control (NCDCs) reports. US National Library of Medicine, Clinicaltrials.gov, has been accessed to get information about ongoing clinical trials. The literature survey started in the first week of April, 2020 and was completed in the first week of August, 2020. The clinical symptoms of COVID-19 patients are generally categorized as critical, severe, moderate and mild or even asymptomatic in descending order in terms of severity. Predictions from experts in different parts of the World concerning the possible impact of the disease in Africa have been on the downside which is due to a lot of glaring factors including poor health facilities and services. 

COVID-19 coronaviridae pandemic disease epidemiology Nigeria.

References (81)

  1. 1 Clinical Characteristics of Coronavirus Disease 2019 in China [DOI]
  2. 2 A pneumonia outbreak associated with a new coronavirus of probable bat origin [DOI]
  3. 3 The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 [DOI]
  4. 4 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [DOI]
  5. 5 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges [DOI]
  6. 6 The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak [DOI]
  7. 7 Origin and evolution of pathogenic coronaviruses [DOI]
  8. 8 Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses [DOI]
  9. 9 Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [DOI]
  10. 10 A CONTROLLED TRIAL OF ANTEPARTUM GLUCOCORTICOID TREATMENT FOR PREVENTION OF THE RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS [DOI]
  11. 11 The COVID‐19 epidemic [DOI]
  12. 12 Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) [DOI]
  13. 13 Coronavirus Disease 2019 (COVID-19): A Perspective from China [DOI]
  14. 14 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread [DOI]
  15. 15 Coronaviruses — drug discovery and therapeutic options [DOI]
  16. 16 Discovery of Seven Novel Mammalian and Avian Coronaviruses in the Genus Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene Source of Gammacoronavirus and Deltacoronavirus [DOI]
  17. 17 A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics [DOI]
  18. 18 Potential interventions for novel coronavirus in China: A systematic review [DOI]
  19. 19 Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence [DOI]
  20. 20 COVID-19, SARS and MERS: are they closely related? [DOI]
  21. 21 New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? [DOI]
  22. 22 Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids [DOI]
  23. 23 Coronaviruses and the cardiovascular system: acute and long-term implications [DOI]
  24. 24 SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far [DOI]
  25. 25 Molecular Evolution of Human Coronavirus Genomes [DOI]
  26. 26 Epidemiology and Clinical Presentations of the Four Human Coronaviruses 229E, HKU1, NL63, and OC43 Detected over 3 Years Using a Novel Multiplex Real-Time PCR Method [DOI]
  27. 27 New insights into the antiviral effects of chloroquine [DOI]
  28. 28 Of chloroquine and COVID-19 [DOI]
  29. 29 Chloroquine for the 2019 novel coronavirus SARS-CoV-2 [DOI]
  30. 30 Insight into 2019 novel coronavirus — An updated interim review and lessons from SARS-CoV and MERS-CoV [DOI]
  31. 31 Combination of RT‐qPCR testing and clinical features for diagnosis of COVID‐19 facilitates management of SARS‐CoV‐2 outbreak [DOI]
  32. 32 Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus [DOI]
  33. 33 CULTIVATION OF VIRUSES FROM A HIGH PROPORTION OF PATIENTS WITH COLDS [DOI]
  34. 34 Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status [DOI]
  35. 35 2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics [DOI]
  36. 36 Italian doctors call for protecting healthcare workers and boosting community surveillance during covid-19 outbreak [DOI]
  37. 37 COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review [DOI]
  38. 38 Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future [DOI]
  39. 39 Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment [DOI]
  40. 40 Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China [DOI]
  41. 41 Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition [DOI]
  42. 42 Comparison of the Antiviral Activity in vitro of some Non-steroidal Anti-inflammatory Drugs [DOI]
  43. 43 Potential Treatments for COVID-19; a Narrative Literature Review.
  44. 44 Antihistaminics, local anesthetics, and other amines as antiviral agents. [DOI]
  45. 45 Can Nigeria contain the COVID-19 outbreak using lessons from recent epidemics? [DOI]
  46. 46 Effect of chloroquine on the growth of animal viruses [DOI]
  47. 47 Rapid detection and monitoring of human coronavirus infections [DOI]
  48. 48 Capitalizing on Nigeria’s demographic dividend: reaping the benefits and diminishing the burdens [DOI]
  49. 49 Evaluation of the AdvanSure™ real-time RT-PCR compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses [DOI]
  50. 50 In-Vitro Antimicrobial Efficacy Study of Borreria Verticillata Stem Bark Extracts Against Some Dermatophytes and Drug Resistant Pathogens [DOI]
  51. 51 Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic [DOI]
  52. 52 COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options [DOI]
  53. 53 RETRACTED: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 [DOI]
  54. 54 Coronavirus disease 2019 (COVID-19): A literature review [DOI]
  55. 55 Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 [DOI]
  56. 56 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies [DOI]
  57. 57 The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19 [DOI]
  58. 58 Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 by WHO-Recommended Hand Rub Formulations and Alcohols [DOI]
  59. 59 Current epidemiological and clinical features of COVID-19; a global perspective from China [DOI]
  60. 60 Current pharmacological treatments for COVID‐19: What's next? [DOI]
  61. 61 COVID-19 and Heart Failure: From Infection to Inflammation and Angiotensin II Stimulation. Searching for Evidence from a New Disease [DOI]
  62. 62 Novel coronavirus (COVID-19): Leveraging telemedicine to optimize care while minimizing exposures and viral transmission [DOI]
  63. 63 Early Transmission Dynamics of Novel Coronavirus (COVID-19) in Nigeria [DOI]
  64. 64 SARS-CoV-2 infection of the nervous system: A review of the literature on neurological involvement in novel coronavirus disease-(COVID-19) [DOI]
  65. 65 COVID-19: From bench to bed side [DOI]
  66. 66 Antiviral therapy in management of COVID-19: a systematic review on current evidence. [DOI]
  67. 67 COVID-19 — Toward a comprehensive understanding of the disease [DOI]
  68. 68 Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the JAHA Editors [DOI]
  69. 69 Medical treatment options for COVID-19 [DOI]
  70. 70 Telephonic triage before surgical ward admission and telemedicine during COVID-19 outbreak in Italy. Effective and easy procedures to reduce in-hospital positivity [DOI]
  71. 71 The COVID-19 epidemic, its mortality, and the role of non-pharmaceutical interventions [DOI]
  72. 72 Sars-CoV-2: A clinical update - II [DOI]
  73. 73 A Review on Novel Coronavirus (Covid-19): Symptoms, Transmission and Diagnosis Tests [DOI]
  74. 74 Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression [DOI]
  75. 75 COVID-19 vaccine trials in Africa [DOI]
  76. 76 COVID-19 risk contagion: Organization and procedures in a South Italy geriatric oncology ward [DOI]
  77. 77 Can Aerosols and Wastewater be Considered as Potential Transmissional Sources of COVID-19 to Humans? [DOI]
  78. 78 Telemedicine in otorhinolaryngological practice during COVID-19 pandemic [DOI]
  79. 79 Epidemiology of Coronavirus Disease (COVID-19) in Nigeria [DOI]
  80. 80 Mechanism of Antiviral Immune Response and COVID-19 Infection
  81. 81 Traveler’s Infections: Understanding SARS-CoV-2 as a Potential Agent [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

69

Page views

0

PDF downloads

35

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.